FDA: Birth Control Studies Needed to Assess Clot Risk

Tuesday, 06 Dec 2011 01:18 PM

 

  Comment  |
   Contact  |
  Print   |
    A   A  
  Copy Shortlink
U.S. regulators pushed for more studies on birth control pills containing the hormone drospirenone, such as Bayer AG’s Yaz, after concluding the risk of blood clots is unclear.
An FDA advisory panel will meet Dec. 8 to review studies that have found conflicting evidence of the chances of clots associated with the oral contraceptives, according to a Food and Drug Administration staff report released today. The panel will also weigh the risks and benefits of the pills.
The FDA published a report in October that found birth control pills containing drospirenone are linked to a higher danger of blood clots relative to standard low-dose versions. Six trials have shown conflicting data on whether the products are linked to a higher risk, the agency said at the time.
“None of the studies to date provides a definitive answer,” FDA said in the report today. “The entire body of studies provides conflicting evidence that cannot easily be reconciled by consideration of any single difference among studies.”
Women taking drospirenone were 74 percent more likely to experience clots than those on low-estrogen pills, the agency said. Drospirenone is similar to the natural female hormone progesterone. Bayer conducted studies that found no increased blood-clot risk.
Bayer’s Yaz and Yasmin brought in $1.5 billion in sales for the German drugmaker last year as its second best-selling drug, less than the $1.8 billion in 2009. Teva Pharmaceutical Industries Ltd. (TEVA) launched a generic version of Yaz in May 2010.
The advisory panel will also evaluate Dec. 9 the risk of blood clots associated with Johnson & Johnson (JNJ)’s Ortho Evra birth control patch. The FDA isn’t required to follow the panel’s recommendations.
Copyright Bloomberg News

© HealthDay

  Comment  |
   Contact  |
  Print   |
  Copy Shortlink
Around the Web
Comments
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 
Find Your Condition
You May Also Like
Around the Web
Most Commented

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAXHEALTH.COM
© Newsmax Media, Inc.
All Rights Reserved
> >